[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974

 
Abstracts

DOI: 10.29090/psa.2026.04.26.9995Pharm Sci Asia 2026; 53(4), 525-533
 

Association between exceeding recommended weight-based doses of first-line antituberculosis drugs and hepatotoxicity during the intensive treatment phase among patients with tuberculosis: A hospital-based case-control study

Khanaphan Hemmarak1, Bhunyabhadh Chaimay2, Somkiattiyos Woradet2*

1 Department of Pharmacy, Sri Naggarindra Hospital, Srinagarindra District, Phatthalung Province, 93000, Thailand
2 Faculty of Health and Sports Science, Phatthalung Campus, Thaksin University, Pa Phayom District, Phatthalung Province, 93210 Thailand


Tuberculosis remains a global health burden. Although first-line antituberculosis drugs are essential for effective treatment, their use may be associated with hepatotoxicity. This study examined the association between the prescribed weight-based doses of isoniazid, rifampicin, pyrazinamide, and ethambutol, and hepatotoxicity during the intensive phase of tuberculosis treatment in routine clinical practice. A hospital-based retrospective case-control study was conducted between January and February 2021 using medical records of patients diagnosed with tuberculosis from 2013 to 2020. A total of 192 subjects were included, comprising 64 cases who developed hepatotoxicity during the intensive phase and 128 matched controls without hepatotoxicity. The exposure variables were the prescribed dose of the first-line antituberculosis drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (ETB), expressed in mg/kg/day and categorized according to whether they were within or exceeded the recommended weight-based dosing ranges. Multivariable logistic regression was performed to evaluate the association between drug dosage and hepatotoxicity after adjustment for age, sex, baseline body weight, HIV infection, baseline serum total bilirubin, baseline serum albumin, and concomitant hepatotoxic medication use. An INH dose exceeding the recommended weight-based range was significantly associated with higher odds of hepatotoxicity (Adjusted Odds Ratios [AOR] = 2.60, 95% Confidence Interval [CI]: 1.03-6.59). In contrast, doses exceeding the recommended range for RIF (AOR = 1.61, 95%CI: 0.21-12.22), PZA (AOR = 0.61, 95% CI: 0.05-7.58), and ETB (AOR = 1.10, 95% CI: 0.34-3.59) were not significantly associated with hepatotoxicity. These findings indicated that an increased odds of hepatotoxicity during the intensive phase of tuberculosis treatment. Careful verification of weight-based INH dosing and appropriate clinical monitoring should therefore be emphasized in routine tuberculosis care.


Keyword:

Tuberculosis; First-line antituberculosis drugs; Isoniazid; Hepatotoxicity




Download full paper (PDF File size: 493.40 KB.)





Vol.53
No.4
October-December 2026

See other volume

 


Vol.53
No.3
July-September 2026

See other volume

 


Vol.53
No.2
April-June 2026

See other volume

 


Vol.53
No.1
January-March 2026

See other volume

 
 
 

Home
Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
Announcement
All Volumes & Issues
Submit Online
Contact us
   
Search
   
Faculty of Pharmacy Mahidol University
Mahidol University



Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2026
    Faculty of Pharmacy, Mahidol University, THAILAND
 

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.